Platelet-derived growth factor (PDGF) is scientifically recognized for its role in wound healing and tissue repair, including the management of scars and scar tissue. PDGF is a naturally occurring protein that regulates cell growth and division, particularly in blood vessels and connective tissue. Its use in scar treatment is primarily supported by evidence from both preclinical and clinical studies. Recombinant human PDGF (becaplermin gel) has been FDA-approved for the treatment of diabetic foot ulcers, a wound type with impaired healing, which indirectly supports its potential for promoting tissue repair and reducing abnormal scar formation.

Mechanistically, PDGF stimulates the migration and proliferation of fibroblasts and smooth muscle cells, which are essential for the formation of new connective tissue during healing. It also promotes angiogenesis (the formation of new blood vessels), which is crucial for supplying nutrients to healing tissue. Some clinical studies and case reports suggest that PDGF-based therapies may enhance wound closure and improve the quality of scar tissue, leading to more organized collagen deposition and potentially less visible or functionally problematic scars. However, while laboratory and animal studies are robust, clinical data specific to the use of PDGF for cosmetic or non-chronic scar treatment in humans is more limited.

Overall, the use of PDGF in scar management is grounded in solid biological rationale and validated in certain wound healing contexts, but direct evidence for its efficacy in treating typical scars or established scar tissue is moderate and ongoing.